Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malignant cells.

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Ono’s therapy Romvimza is administered twice-weekly compared to Daiichi Sankyo’s twice-daily Turalio. Northern TK Venture (NTK), a subsidiary of IHH Healthcare, has submitted an expert report ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

There are various types of injectable medications for weight loss, which can be injected into the stomach or other areas. These include commonly prescribed drugs such as Ozempic or Wegovy (semaglutide ...

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.